Biot-KTWGQYWQV-OH

Ref. 3D-PP43770

Informations sur le produit

• Nom: Biot-KTWGQYWQV-OH
• Synonymes: Biot-Lys-Thr-Trp-Gly-Gln-Tyr-Trp-Gln-Val-OH

Description

Peptide Biot-KTWGQYWQV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Biot-KTWGQYWQV-OH include the following: and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide WJ Lesterhuis , G Schreibelt, NM Scharenborg - Cancer immunology , 2011 - Springerhttps://link.springer.com/article/10.1007/s00262-010-0942-x Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors PA Sotiropoulou, SA Perez , V Voelter, H Echner - Cancer Immunology , 2003 - Springerhttps://link.springer.com/article/10.1007/s00262-003-0420-9 Ii-Key/HER-2/neu (776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2 NN Sotiriadou, NL Kallinteris, AD Gritzapis - Cancer Immunology , 2007 - Springerhttps://link.springer.com/article/10.1007/s00262-006-0213-z Competition among peptides in melanoma vaccines for binding to MHC molecules LW Thompson, CF Garbee, S Hibbitts - Journal of , 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/11000/competition_among_peptides_in_melanoma_vaccines.2.aspx Mass-spectrometric evaluation of HLA-A* 0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100 JCA Skipper, PH Gulden - journal of cancer, 1999 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1097-0215(19990827)82:5%3C669::AID-IJC9%3E3.0.CO;2-%23 Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1 J Lai, Y Wang, SS Wu, D Ding, ZY Sun, Y Zhang - Biomaterials, 2018 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S014296121830437X Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers C Yee , PA Savage, PP Lee, MM Davis - The Journal of , 1999 - journals.aai.orghttps://journals.aai.org/jimmunol/article/162/4/2227/43090 Transporter (TAP)-and proteasome-independent presentation of a melanoma-associated tyrosinase epitope C Wölfel, I Drexler, A Van Pel, T Thres - journal of cancer, 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0215(20001101)88:3%3C432::AID-IJC16%3E3.0.CO;2-9 Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2. 1-restricted anti-melanoma ABH Barker, MWJ Schreurs, G Tafazzul - journal of cancer, 1995 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.2910620118

• Marque: Biosynth